The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 23, 2010

Filed:

Mar. 19, 2002
Applicants:

Phillip John Birch, Cambridge, GB;

Ann Gail Hayes, Cambridge, GB;

Peter James Watts, Nottingham, GB;

Jonathan David Castile, Nottingham, GB;

Inventors:

Phillip John Birch, Cambridge, GB;

Ann Gail Hayes, Cambridge, GB;

Peter James Watts, Nottingham, GB;

Jonathan David Castile, Nottingham, GB;

Assignees:

Vernalis (R&D) Limited, Winnersh, Berkshire, GB;

Archimedes Development Limited, Nottingham, GB;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 43/42 (2006.01); A61K 31/35 (2006.01); A61K 31/715 (2006.01); A61F 13/00 (2006.01); C07D 498/00 (2006.01); C07D 513/00 (2006.01); C07D 515/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, C, of 0.2 ng/ml or greater which is maintained for a duration Tof at least 2 hours.


Find Patent Forward Citations

Loading…